Investigation of new synthetic compounds: 4-(methyl sulfanyl)phenyl-1,3,4-thiadiazol-2-amine and 1-methyl-[4-(methyl sulfanyl)phenyl]-1,3,4-thiadiazol-2-amine, for anti-cancerous activity and for p53 anti-cancer gene expression on glioblastoma cell cultures (LN-229)

Title : Investigation of new synthetic compounds: 4-(methyl sulfanyl)phenyl-1,3,4-thiadiazol-2-amine and 1-methyl-[4-(methyl sulfanyl)phenyl]-1,3,4-thiadiazol-2-amine, for anti-cancerous activity and for p53 anti-cancer gene expression on glioblastoma cell cultures (LN-229)

Abstract:

Glioblastoma Multiforme (GBM) is a stage IV brain tumour is complex and deadly diseases. There is no promising therapeutic applications for GBM, and so many drugs are developed, and screened in pre- clinical/clinical tests. To understand the mechanism of GBM cancer causes the cell lines models were considered, of which LN-229 is used in the present study. There exists newly synthesized thiadiazole derivatives, namely, 4-(methyl sulfanyl) phenyl-1,3 ,4-thiadiazol-2 amine and 1- methyl- [4-(methyl sulfanyl) phenyl]-1,3,4-thiadiazol-2-amine, that needs to be tested for their anti-cancer activity. The research gap of not using GBM cell lines extensively for drug screening are examined for current studies. Hence, LN-229 is used as in vitro model to assess the anti-cancer activity of the given thiadiazole derivatives. It has to be noted that this is a small-scale study involving few samples, trying to determine only the IC50 value in case of LN-229 cells. The feasibility of the study outcomes is notable enough to consider for further analysis. Hence, there is cancer gene expression carried out to determine upregulation/downregulation of genes such as TP53, and EGFR, mutated in cancer cells. So the MTT assay performed for cell ability testing and RT-qPCR for gene expression analysis were employed for the current study. Overall, the aim is to integrate drug screening with disease of interest. The present studies confirms for new synthetic thiadiazole compounds are proven to have potential anti- cancer activity against GBM cell line LN-229, with upregulation of TP53 gene and downregulation of EGFR gene which promises the experimental design for anticancer chemotherapeutics.

Key words: Glioblastoma Multiforme, LN228 cell lines, P53, EGFR, Thiadiazol-derivatives.

Biography:

Dr. Prabha M is an Associate Professor at RIT, located in Bengaluru, India. She has published 20 research articles and 8 conference proceedings publications. She was Post doctoral Fellow for CSIR RA fellowship 2008 at IISc. She has received the Distinguished woman in health and medical sciences-Biochemistry — From Venus International foundation, Chennai. 2019. She has been awarded as Bharat Shiksha Gaurava Puraskar – 2022 and Excellence for Best Educationist Award-2022 by KTK foundation, New Delhi. She got certificate for NPTEL Domain star–Biotechnology—Biosciences 2022. She has received the certificate for winner for Women Researcher Award– In the International Scientist Awards on Engineering, Science and Medicine, held on 04-Nov-2022, Organized by VDGOOD® Professional Association. She is an invited editor for Journal of Clinical Science & Translational Medicine, Journal of Biomedicine and Biosensor and Biochemical Engineering & Bioprocess Technology. She is invited as reviewer constantly for. Clinical and Translational oncology Springer publications, Cancer Biomarker, Journal of Neurochemistry and for Indian journal of Neurosciences. She is guiding PhD and many MTech /BE project students.